New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:07 EDTARIA, REPH, HOLI, BMRN, AEO, RSPP, CSTM, ATW, ALE, SNSS, NMM, CAB, ATHLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) coverage transitioned with a Neutral at UBS... Allete (ALE) initiated with a Neutral at JPMorgan... American Eagle (AEO) initiated with a Fair Value at CRT Capital... Athlon Energy (ATHL) initiated with a Buy at Mizuho... Atwood Oceanics (ATW) initiated with a Hold at Deutsche Bank... BioMarin (BMRN) coverage transitioned with a Buy at UBS... Cabela's (CAB) initiated with a Neutral at Goldman... Constellium (CSTM) initiated with a Buy at Sterne Agee... Hollysys Automation (HOLI) initiated with a Buy at Goldman... Navios Maritime Partners (NMM) initiated with a Buy at Jefferies... RSP Permian (RSPP) initiated with a Buy at Mizuho... Recro Pharma (REPH) initiated with a Buy at Aegis... Sunesis (SNSS) initiated with a Buy at UBS.
News For ARIA;ALE;AEO;ATHL;ATW;BMRN;CAB;CSTM;HOLI;NMM;RSPP;REPH;SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 10, 2014
06:40 EDTSNSSSunesis upgraded to Buy from Hold at Cantor
Subscribe for More Information
06:11 EDTAEOAmerican Eagle upgraded to Outperform from Market Perform at BMO Capital
December 9, 2014
13:31 EDTREPHRecro Pharma downgraded to Hold from Buy at Aegis
12:30 EDTNMMWells Fargo to hold a symposium
Subscribe for More Information
12:22 EDTBMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTAEOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Eagle (AEO) upgraded to Outperform from Perform at Oppenheimer... Concho Resources (CXO) upgraded to Outperform from Neutral at Macquarie... Hanmi Financial (HAFC) upgraded to Outperform from Market Perform at FBR Capital... LHC Group (LHCG) upgraded to Outperform from Underperform at Credit Suisse... Lincoln Electric (LECO) upgraded to Buy from Neutral at Longbow... Northeast Utilities (NU) upgraded to Outperform from Neutral at Macquarie... SM Energy (SM) upgraded to Outperform from Neutral at Macquarie... Volcano (VOLC) upgraded at Needham... Wells Fargo sees fewer distractions for lululemon (LULU), upgrades shares... Xcel Energy (XEL) upgraded to Outperform from Neutral at Macquarie... lululemon (LULU) upgraded to Outperform from Market Perform at Wells Fargo.
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTBMRNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
07:33 EDTHOLIJPMorgan to hold a forum
Subscribe for More Information
05:56 EDTAEOAmerican Eagle upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded American Eagle to Outperform with a $14 price target.
December 8, 2014
13:34 EDTSNSSSunesis announces positive results from ongoing trial of Vosaroxin
Subscribe for More Information
12:40 EDTSNSSOn The Fly: Midday Wrap
Subscribe for More Information
10:20 EDTAEOOptions with decreasing implied volatility
Subscribe for More Information
09:29 EDTSNSSSunesis risk/reward attractive, says RBC Capital
RBC Capital believes that the EU could approve Sunesis' vosaroxin drug. The firm says that an EU approval would lift the stock by about 35%, and ir keeps a $3 price target and Sector Perform rating on the shares.
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
05:51 EDTSNSSSunesis to host conference call
Conference call to discuss results from the Phase 3 VALOR trial of vosaroxin and cytarabine will be held on December 9 at 1:30 pm. Webcast Link
December 7, 2014
16:42 EDTSNSSSunesis announces presentation of Phase 3 VALOR trial results
Subscribe for More Information
December 6, 2014
09:15 EDTSNSSSunesis to hold a meeting
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use